Summary Ninety-seven cases of chronic myelomonocytic leukaemia (CMML) were examined retrospectively for survival and possible prognostic factors including age, total white cell count, peripheral blood and bone marrow monocyte counts, % double esterase (DE) positive cells in bone marrow and serum lysozyme. Age, absolute monocyte counts and serum lysozyme proved to be significant independent prognostic indicators but Cox model analyses showed serum lysozyme to be the most important factor whether taken as a continuous or discrete (two groups) variable. Twelve cases of second malignancy were found, including 2 cases of multiple myeloma, but this was not significantly greater than expected when compared with an age and sex matched group.
Although cases with features of CMML have been identified
Survival data was collected by examination of case notes for many years and referred to under a variety of terms by one of the authors (ANS), and from the Yorkshire (Broun, 1969; Linman, 1970; Saarni & Linman, 1971 ; Regional Cancer Registry. The immediate cause of death Miescher & Farquet, 1974; Sexauer et al., 1974; Geary et al., (where applicable) was taken from the death certificate or 1975), it was only with the adoption of a fixed set of post-mortem report and survivals calculated from initial diagnostic criteria (Bennett et al., 1982) that comparisons diagnosis. could be made between studies by different centres. Chronic
In total 97 cases were studied; 48 males and 49 females myelomonocytic leukaemia (CMML) is now widely classified (male/female ratio 1:1) and complete survival and follow up with the myelodysplastic syndromes (MDS) and charac-data were available in 79 cases. terised haematologically by the presence of increased and often atypical monocytes in the peripheral blood, together Morphological, cytochemical and serum lysozyme with evidence of bone marrow dysplasia in any or all of the investigations cell lines. CMML may however be viewed as a spectrum of diseases with wide variations in peripheral blood leucocyte Morphology was examined on May-Grunwald-Giemsa counts and clinical course and someinvestigatorstained peripheral blood and bone marrow smears and the CMML shoud clin l considered as a distinct entity, with diagnosis of CMML made according to FAB criteria CMML should be (Bennett et al., 1982) . Minimal diagnostic criteria for features of both myeloproliferative and myelodysplastic CMML were the presence of a total peripheral blood disorders (Solal-Celigny et al., 1984; Milner et al., 1977 Haznedar, 1985; Sans-Sabrafen et al., 1986; (Altman et al., 1974; Thomas et al., 1981 (cx-naphthyl acetate and chloroacetate) esterase staining, previously associated with MDS (Scott et al., 1983 , were cytochemically assessed by conventional techniques Matenials and methods (Yam et al., 1971) .
Serum lysozyme was estimated as previously described Patients studied (Milligan et al., 1984) by spectrophotometric measurement of Cases examined were referred to this department for micrococcus lysodeikticus lysis; the normal range being 150-diagnosis during the period [1981] [1982] [1983] [1984] [1985] [1986] . Blood and marrow 500 uml-1 where 1 unit is defined as the amount of enzyme specimens were taken at diagnosis into EDTA for causing a decrease in A450 of 0.001 min-t at 37°C. morphological and cytochemical studies and a serum sample was also taken in most cases for lysozyme estimation. Date Statistical analysis of birth and age at diagnosis were noted as were details of Individual variables were examined for survival using the survival and the presence of second malignancies, log-rank test (Peto et al., 1977) and also analysed separately allowing for age as a stratified variable (grouped <75 yrs Correspondence: C.S. Scott. and >75 yrs). Received 6 February 1987.
Variables found to be significant or of borderline significance at the 5% level were further investigated using 60
Cox's proportional hazards model (Cox, 1972) (Tricot et al., 1985) . Statistical relationships for the data were assessed using significant (P=0.013) as a prognostic factor (Figure 4 ) with Spearmans non-parametric rank correlation coefficient the high count group having a median survival from (Table,1 Serum lysozyme was divided into two groups (<2,500 and Survival data >2,500 u ml-1); a cut-off point selected arbitrarily as five times the normal upper limit, the low lysozyme group Survival was calculated using the Kaplan-Meier method to surviving longer than those with levels exceeding cancer death and this gave a median survival for all patients 2,500uml-' (P=0.028; Figure 5 ). haemopoietic) generally (Ho et al., 1982; Stefani, 1985; Scott et al., 1986 apart from the obvious benefits of having prognostic (Norfolk etdat., 1985) .
information available on any given patient, treatment might
The median survival in our study (18 months) was similar bfmorerationalalp anned.
to two earlier studies (Solal-Celigny et al., 1984;  beWmoe hravetshownally planned. CMML atietswthAlessandrino et al., 1985; median survivals 15.8 and 18
We have shown that CMML patients with a high months respectively), although less than that reported monocyte counts but this did not appear to be related to recently (Groupe Francais de Cytogenetique Hematologique, monocytic tumour load, as reflected by monocytic 1986; median survival 27 months), confirming that the infiltration of bone marrow. In contrast to a recent study disease has a poor prognosis with few patients surviving (Groupe Francais de Cytogenetique, 1986) , which reported more than two years following clinical presentation. 59 cases of high count (d>5.0 x 10-19) CMML in a total of It has also been suggested that the incidence of second 120 (49.2%) patients, we found only a small number (17/97: malignancies in CMML may be increased (Copplestone et 17 .5%) Reasons for this discrepancy are unclear but may be al., Mufti et al., 1983) and some authors consider that related to sampling methods and diagnostic criteria a picture of CMML may occur as part of a paraneoplastic employed. In our survey, all cases with primary dysplasia syndrome (Haznedar, 1985; Raz et al., 1984 ; Sans-Sabrafen referred from a wide population area were examined as et al., 1986) . Seven of our series of patients had a carcinoma potential 'low count' CMML and, conversely, we reviewed present before the diagnosis of CMML was made and it is all cases of atypical chronic granulocytic leukaemia (CGL) therefore possible that in these cases the picture of dysplasia and myeloproliferative disease as potential 'high count' cases and monocytosis was a result of the carcinoma, rather than and cases were diagnosed as CMML only if they fulfilled the representing the development of a new tumour. However, FAB criteria for this diagnosis. It is also accepted that it can when the 10 cases of carcinoma and 2 of myeloma were be difficult to differentiate between phl negative CGL and analyzed against an age and sex matched group, no CMML.
statistical increase of second malignancy was found. Increased BM monocytic components were found in many It can be argued that since paraprotein was not sought of our cases (mean 12.5%BM monocytes), in contrast to routinely in all cases it is possible that the true incidence early morphological descriptions (Broun, 1969; Miescher & (Barnard et al., 1979) probably of granulocytic origin so the but this is presumably uncommon as all 12 patients with association of DE +ve cells and BM monocytes cannot be paraproteinaemia in a recent study (Group Francais de explained on the basis that the same cells are being stained.
Cytogenetique Hematologique, 1986) showed some increase Rather it would appear that the increased monocytic in BM plasma cells. It has been proposed in another study involvement of BM is associated with the abnormality (Copplestone et al., 1986 ) that the occurrence of B-cell (possibly due to gene derepression) in enzyme expression that malignancy in MDS does not represent a true second tumour causes granulocyte precursors to express monocyteand may be part of the same clonal disturbance, though we associated ANA in addition to chloroacetate esterase found no direct evidence for this in our study.
As in leukaemia generally, age significantly influenced
In conclusion, we have analysed 97 cases of CMML for prognosis, indepe enetly of the other factors examined prognostic factors and found that age, PB monocyte count However, it is difficult to say whether this means the disease and serum lysozyme levels are significant single independent is inherently more aggressive in an older population or prognostic factors. Multiple regression analysis showed whether, as might be expected, older people simply have a serum lysozyme to be the most important of these although higher overall mortality with the CMML contributing in a the other factors remained significant even when lysozyme non-specific way.
was taken into account. Use of these easily available features Serum lysozyme was the single most valuable prognostic should allow better prediction of survival in CMML factor whether taken as a discrete or continuous variable.
Serum lysozyme is elevated in many types of myeloid leukaemias, particularly of monocytic type (Milligan et at., 1984; Norfolk et at., 1985; , and shows
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